The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments
The projected U.S. market for biodefense-related rapid pathogen detection devices is valued at $214.2 million in 2015. The total market is projected to grow at a compound annual growth rate (CAGR) of 8% from 2016 through 2021 and reach $248 million by 2016 and $364 million by 2021.
- An overview of biodefense-related rapid pathogen identification and treatment markets, with a concentration on activities within the U.S.
- Analyses of global market trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021.
- Identification of substances that can be weaponized for either cilivilian or military destruction rapidly and accurately.
- Information on infectious agents including smallpox, anthrax, plague and tularemia, as well as coverage of potentially harmful chemical toxins that are used in biological warfare situtations including sarin gas, ricin and botulinum.
- Outlines of the political and social landscape of biodefense, focusing on the issues of survelliance, coordination of resources and financing.
- Profiles of major players in the industry.
The market report organizes information from diverse sources into a cohesive unit that includes an industry overview; overview of infectious agents with detection, vaccine and treatment information; biodefense-related diagnostic tools; current research and emerging industries related to rapid pathogen identification; biodefense-related pathogen identification product patents; and a comprehensive directory of assay, sensor, vaccine and treatment companies.
Peggy S. Lehr is the BCC Research analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder and an MS in Communication from the University of Denver. Ms. Lehr has worked within the publishing industry for both for-profit and not-for-profit organizations, and she has specialized in marketing reports on the medical industry for 20 years. Her latest report, HLC092C—Healthcare-Acquired Infections: Devices, Pharmaceuticals and Environmental Products was published in May 2015.